Discontinuations reasons	Infliximab	Adalimumab	Etanercept	p
	(n=156)	(n=24)	(n=32)
Loss of the efficacy	32 (20.5%)	7 (29.2%)	–	<0.05
Psoriasis de novo	10 (6.4%)	1 (4.2%)	2 (6.3%)	NS
Drug hepatitis	3 (1.9%)	1 (4.2%)	1 (3.1)	NS
Pulmonary tuberculosis and conversion of PPD skin test	3/3 (3.8%)	–	–	NA
All	51 (32/6%)	9 (37.5%	3 (9.4%)	<0.05